We are live on ! Find out more
RPSM

Royalty Pharma Sub-Manager Portfolio holdings

AUM $242M
This Fund
S&P 500
This Quarter Est. Return
+18.38%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$171M
AUM Growth
–
Cap. Flow
+$167M
Cap. Flow %
97.32%
Top 10 Hldgs %
100%
Holding
4
New
4
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$61M
2
ZBIO
Zenas BioPharma
ZBIO
+$41.5M
3
BHVN icon
Biohaven
BHVN
+$36.4M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$27.8M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
1
Cytokinetics
CYTK
$9.72B
$62.3M 36.36%
+980,392
New +$61M
ZBIO
2
Zenas BioPharma
ZBIO
$2.08B
$45.9M 26.77%
+1,263,150
New +$41.5M
BHVN icon
3
Biohaven
BHVN
$2.1B
$33.2M 19.35%
+2,936,507
New +$36.4M
BCRX icon
4
BioCryst Pharmaceuticals
BCRX
$2.22B
$30M 17.51%
+3,846,154
New +$27.8M

Similar funds

FH
Financial Harvest Winter Park, Florida $242M AUM 23.25% 1-Year Est. Return
SA
Sunesis Advisors Overland Park, Kansas $242M AUM 15.73% 1-Year Est. Return
TFP
TrueWealth Financial Partners Bellevue, Washington $242M AUM 14.39% 1-Year Est. Return
WCP
Wealthcare Capital Partners West Chester, Pennsylvania $242M AUM 18.96% 1-Year Est. Return
UI
Unconventional Investor Portsmouth, New Hampshire $242M AUM 18.7% 1-Year Est. Return
ACP
Arcus Capital Partners Atlanta, Georgia $242M AUM 20.33% 1-Year Est. Return
DEA
DoubleLine ETF Adviser Tampa, Florida $242M AUM 7.85% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $242M AUM 17.72% 1-Year Est. Return

Royalty Pharma Sub-Manager's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for Royalty Pharma Sub-Manager, which disclosed 4 positions worth $171M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Cytokinetics: 980,392 shares worth $62.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Royalty Pharma Sub-Manager's largest Q4 2025 buy was Cytokinetics: 980,392 shares worth $62.3M.
  • Royalty Pharma Sub-Manager's ten largest holdings make up 100% of its $171M portfolio in Q4 2025.
  • Royalty Pharma Sub-Manager disclosed 4 positions in Q4 2025, its first 13F filing on record.

Based on Royalty Pharma Sub-Manager's 13F filing for Q4 2025, filed 1 Apr 2026.